JP6404834B2 - インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 - Google Patents

インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 Download PDF

Info

Publication number
JP6404834B2
JP6404834B2 JP2015556042A JP2015556042A JP6404834B2 JP 6404834 B2 JP6404834 B2 JP 6404834B2 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 6404834 B2 JP6404834 B2 JP 6404834B2
Authority
JP
Japan
Prior art keywords
acid
diabetes
level
biomarkers
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509222A (ja
JP2016509222A5 (enExample
Inventor
ゴール、ウォルター
コブ、ジェフリー、エドモンド
パッパン、カーク、レイン
Original Assignee
メタボロン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボロン，インコーポレイテッド filed Critical メタボロン，インコーポレイテッド
Publication of JP2016509222A publication Critical patent/JP2016509222A/ja
Publication of JP2016509222A5 publication Critical patent/JP2016509222A5/ja
Application granted granted Critical
Publication of JP6404834B2 publication Critical patent/JP6404834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2015556042A 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 Active JP6404834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361758924P 2013-01-31 2013-01-31
US61/758,924 2013-01-31
PCT/US2014/011759 WO2014120449A1 (en) 2013-01-31 2014-01-16 Biomarkers related to insulin resistance progression and methods using the same

Publications (3)

Publication Number Publication Date
JP2016509222A JP2016509222A (ja) 2016-03-24
JP2016509222A5 JP2016509222A5 (enExample) 2017-02-09
JP6404834B2 true JP6404834B2 (ja) 2018-10-17

Family

ID=51262841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556042A Active JP6404834B2 (ja) 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法

Country Status (5)

Country Link
US (2) US9910047B2 (enExample)
EP (2) EP2951313B1 (enExample)
JP (1) JP6404834B2 (enExample)
ES (2) ES2987582T3 (enExample)
WO (1) WO2014120449A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014243259B2 (en) * 2013-03-28 2019-04-18 Société des Produits Nestlé S.A. Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
CN109154619A (zh) * 2016-05-17 2019-01-04 国立大学法人大阪大学 用于判定糖尿病的血液试样的分析方法及系统
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
ES3004083T3 (en) * 2016-12-19 2025-03-11 Metabolon Inc Mass spectrometry assay method for detection and quantitation of kidney function metabolites
WO2018150077A1 (en) * 2017-02-16 2018-08-23 Afekta Technologies Oy Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases
JP7337701B2 (ja) * 2017-03-31 2023-09-04 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー インスリン及びｃ－ペプチドの定量の方法
EP3401683A1 (en) * 2017-05-10 2018-11-14 Eberhard Karls Universität Tübingen Medizinische Fakultät Diagnosing metabolic disease by the use of a biomarker
EP3740200B1 (en) * 2018-01-17 2024-12-11 University Of Southampton Methods to predict risk of and to stratify sarcopenia and nad deficiency
US20210396766A1 (en) * 2018-09-27 2021-12-23 Societe Des Produits Nestle S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
CA3177108A1 (en) * 2020-04-27 2021-11-04 Wayne R. Matson Detection and modification of gut microbial population
CN112149311B (zh) * 2020-10-12 2021-10-26 北京中恒利华石油技术研究所 一种基于数量规约的非线性多元统计回归测井曲线预测方法
CN112843036A (zh) * 2021-01-29 2021-05-28 中国药科大学 β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用
CN116087486B (zh) * 2021-11-08 2024-02-02 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
EP4504961A1 (en) * 2022-04-07 2025-02-12 Need4Health B.V. Method for determining insulin dosage
JP7736971B2 (ja) * 2022-10-18 2025-09-10 株式会社オルトメディコ 糖尿病境界域者のスクリーニング方法
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1718327B1 (en) 2003-06-20 2015-01-07 University of Florida Biomarkers for differentiating between type 1 and type 2 diabetes
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
ES2525345T3 (es) * 2006-03-24 2014-12-22 Metanomics Gmbh Procedimiento de diagnóstico de diabetes de tipo II
EP2164977B1 (en) * 2007-07-17 2013-10-30 Metabolon, Inc. Biomarkers for pre-diabetes and methods using the same
US20110311650A1 (en) 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
EP2313773A1 (en) * 2008-07-15 2011-04-27 Metanomics Health GmbH Means and methods diagnosing gastric bypass and conditions related thereto
US20120122981A1 (en) 2009-03-31 2012-05-17 Yun Fu Hu Biomarkers Related to Insulin Resistance and Methods using the Same
US8367418B2 (en) 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
US20150065366A1 (en) * 2011-11-11 2015-03-05 Metabolon, Inc. Biomarkers for Bladder Cancer and Methods Using the Same
AU2012347557A1 (en) * 2011-12-09 2014-07-03 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same

Also Published As

Publication number Publication date
EP2951313A1 (en) 2015-12-09
JP2016509222A (ja) 2016-03-24
US20150362510A1 (en) 2015-12-17
EP3321686A1 (en) 2018-05-16
HK1217516A1 (en) 2017-01-13
US9910047B2 (en) 2018-03-06
EP2951313B1 (en) 2018-03-07
US20180203021A1 (en) 2018-07-19
EP3321686B1 (en) 2024-03-13
EP2951313A4 (en) 2016-11-02
WO2014120449A1 (en) 2014-08-07
ES2987582T3 (es) 2024-11-15
ES2669620T3 (es) 2018-05-28

Similar Documents

Publication Publication Date Title
EP3321686B1 (en) Biomarkers related to insulin resistance progression and methods using the same
JP5876918B2 (ja) 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法
US20120122981A1 (en) Biomarkers Related to Insulin Resistance and Methods using the Same
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
CN103403548A (zh) 用于预测糖尿病的工具和方法
AU2014216035B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
HK1217516B (en) Biomarkers related to insulin resistance progression and methods using the same
Petersson Exploring Metabolic and Functional Changes in Stroke Patients: Insights from a Urinary and Blood-Derived Metabolomic Study
AU2016206265B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
HK1142636B (en) Biomarkers for pre-diabetes and methods using the same
Al-Najdawi et al. Assessment of triglyceride glucose index and triglyceride to HDL cholesterol ratio as markers of insulin resistance defined by the Homeostatic Model Assessment 2 in Middle Eastern adults with excess adiposity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180913

R150 Certificate of patent or registration of utility model

Ref document number: 6404834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250